科伦博泰生物(06990)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06990 科伦博泰生物

交易中 07-21 11:47:29

503.500

-0.500

-0.10%

最高523.000	最低494.800	成交量48.23万
今开509.000	昨收504.000	日振幅5.60%
总市值1,203亿	流通市值891.20亿	总股本2.39亿
成交额2.44亿	换手率0.27%	流通股本1.77亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06990","market":"HK","secType":"STK","nameCN":"科伦博泰生物","latestPrice":503.5,"timestamp":1784605577264,"preClose":504,"halted":0,"volume":482252,"delay":0,"changeRate":-0.000992063492063492,"floatShares":177000000,"shares":239000000,"eps":-1.9195417393929413,"marketStatus":"交易中","change":-0.5,"latestTime":"07-21 11:47:29","open":509,"high":523,"low":494.8,"amount":243585887,"amplitude":0.055952,"askPrice":503.5,"askSize":1000,"bidPrice":502.5,"bidSize":5200,"shortable":3,"etf":0,"ttmEps":-1.9195417393929413,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1784606400000},"marketStatusCode":2,"adr":0,"listingDate":1689004800000,"exchange":"SEHK","adjPreClose":504,"openAndCloseTimeList":[[1784597400000,1784606400000],[1784610000000,1784620800000]],"volumeRatio":0.695803,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06990","defaultTab":"news","newsList":[{"id":"1138741609","title":"异动解读｜科伦博泰生物盘中上涨3.08%，多家投行上调目标价叠加机构举牌潮延续","url":"https://stock-news.laohu8.com/highlight/detail?id=1138741609","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138741609?lang=zh_cn&edition=full","pubTime":"2026-07-21 09:47","pubTimestamp":1784598446,"startTime":"0","endTime":"0","summary":"7月21日，科伦博泰生物盘中上涨3.08%，报519.5港元，成交额6239.98万港元。消息面上，近期多家国际投行密集上调公司目标价，摩根大通将目标价升至648港元，高盛上调至582.95港元并维持\"买入\"评级，瑞银看好公司全球扩张前景。科伦博泰生物是一家主要从事肿瘤学、免疫学及其他治疗领域创新药物研发、制造及商业化的公司，核心产品包括TROP2 ADC等抗体药物偶联物。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652293921","title":"港股异动 | 科伦博泰生物(06990.HK)盘中涨超7% sac-TMT联合疗法临床研究达主要终点 瑞银看好全球扩张","url":"https://stock-news.laohu8.com/highlight/detail?id=2652293921","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652293921?lang=zh_cn&edition=full","pubTime":"2026-07-20 15:25","pubTimestamp":1784532339,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","LU0196878994.USD","06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652269822","title":"创新药板块活跃 荣昌生物(09995)涨7.28% 多支头部公募大举举牌港股创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2652269822","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652269822?lang=zh_cn&edition=full","pubTime":"2026-07-20 10:26","pubTimestamp":1784514372,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药板块活跃，荣昌生物 涨7.28%，歌礼制药-B涨6.81%，科伦博泰生物涨6.70%，康诺亚-B涨6.25%，康方生物涨5.83%，药明合联涨5.53%，石药集团涨4.94%，三生制药涨5.02%，信达生物涨4.55%，药明生物涨4.60%，恒瑞医药涨4.00%，百济神州涨3.88%。头部机构密集触及举牌线，凸显对创新药板块的看好。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/MzQyYjVhODQ3ZWY1M2M1MGY5NWIyMTYzODE1MzIxNzE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MzQyYjVhODQ3ZWY1M2M1MGY5NWIyMTYzODE1MzIxNzE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986240","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0516423174.USD","KCAI","BK1576","LU0359201612.USD","LU1242518931.SGD","LU1720050803.USD","01276","LU0043850808.USD","LU0708995583.HKD","LU0516422440.USD","LU1242518857.USD","BK1593","06990","SG9999002463.SGD","VXUS","LU0348827113.USD","06160","LU0417516738.SGD","01672","09926","02269","LU2328871848.SGD","09995","IBBQ","01801","02162","BK1588","IE00BZ08YT58.USD","BK4585","01093","159992","HK0000165453.HKD","LU0196878994.USD","LU1951186391.HKD","LU2399975544.HKD","MEDX","KURE","01530","LU2097828474.EUR","BK0239","LU0979878070.USD","LU0327786744.USD","LU0052750758.USD","LU1064130708.USD","02268","LU1226288170.HKD","LU0348735423.USD","LU0516422366.SGD","06978","688331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180073163","title":"异动解读｜科伦博泰生物盘中上涨3.41%，多家投行上调目标价叠加生物科技板块集体反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1180073163","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180073163?lang=zh_cn&edition=full","pubTime":"2026-07-20 09:44","pubTimestamp":1784511853,"startTime":"0","endTime":"0","summary":"7月20日，科伦博泰生物盘中上涨3.41%，报514.0港元，成交额9828.4万港元。消息面上，此前公司核心产品TROP2 ADC芦康沙妥珠单抗联合帕博利珠单抗一线治疗PD-L1阴性NSCLC的III期研究达主要终点后，股价经历连续回调。板块层面，今日生物科技板块集体反弹，荣昌生物涨5.97%、康方生物涨4.13%、三生制药涨3.59%、信达生物涨3.54%、百济神州涨3.39%，板块情绪回暖带动个股企稳回升。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652409569","title":"小摩：升科伦博泰生物(06990.HK)目标价至648港元 公司研究取得积极成果","url":"https://stock-news.laohu8.com/highlight/detail?id=2652409569","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652409569?lang=zh_cn&edition=full","pubTime":"2026-07-17 17:00","pubTimestamp":1784278857,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06990","LU0196878994.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135284658","title":"异动解读｜科伦博泰生物盘中下跌3.25%，临床利好兑现后延续回调叠加生物科技板块集体走弱","url":"https://stock-news.laohu8.com/highlight/detail?id=1135284658","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135284658?lang=zh_cn&edition=full","pubTime":"2026-07-17 09:56","pubTimestamp":1784253396,"startTime":"0","endTime":"0","summary":"7月17日，科伦博泰生物盘中下跌3.25%，报501.5港元，成交额1.92亿港元。公司于7月15日公布核心产品TROP2 ADC芦康沙妥珠单抗联合帕博利珠单抗一线治疗PD-L1阴性NSCLC的III期研究达主要终点，当日股价大涨逾11%，此后连续两个交易日出现利好兑现后的获利回吐。今日生物科技板块整体大幅走弱，康方生物跌8.5%、三生制药跌6.92%、荣昌生物跌6.53%、信达生物跌2.34%、百济神州跌2.1%，板块系统性抛压进一步加剧个股回调。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651131604","title":"高盛：科伦博泰生物维持“买入”评级 目标价上调至582.95港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2651131604","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651131604?lang=zh_cn&edition=full","pubTime":"2026-07-16 12:48","pubTimestamp":1784177280,"startTime":"0","endTime":"0","summary":"　　高盛发布研报称，上调科伦博泰生物2027及2028年每股盈利预测至7.51元及14.46元人民币，目标价由561.4港元上调至582.95港元，维持“买入”评级，认为科伦博泰有望成为具影响力的全球ADC药企。该行预期，临床研究的正面结果为sac-TMT在治疗1L NSCLC研究的关键一步，将Lung06的成功率由81%上调至90%，海外1L NSCLC PD-L1 肿瘤比例分数<50%适应症成功率由54%上调至63%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2026-07-16/doc-inihyqhh1192539.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["EWH","06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149134058","title":"异动解读｜科伦博泰生物盘中下跌3.45%，前日临床数据利好兑现后冲高回落","url":"https://stock-news.laohu8.com/highlight/detail?id=1149134058","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149134058?lang=zh_cn&edition=full","pubTime":"2026-07-16 10:04","pubTimestamp":1784167495,"startTime":"0","endTime":"0","summary":"7月16日，科伦博泰生物盘中下跌3.45%，报515.5港元，成交额1.22亿港元。公司前一交易日公布核心产品TROP2 ADC芦康沙妥珠单抗联合帕博利珠单抗一线治疗PD-L1阴性NSCLC的III期研究达到主要终点，当日股价大涨逾11%。今日早盘开涨4.19%后迅速回落，呈现典型的利好兑现冲高回调走势。此外，生物科技板块整体承压，信达生物跌2.52%、康方生物跌1.26%、三生制药跌1.16%，板块情绪偏弱加剧回调。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651249751","title":"高盛：科伦博泰生物(06990.HK)sac-TMT联合疗法临床研究达主要终点 维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2651249751","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651249751?lang=zh_cn&edition=full","pubTime":"2026-07-16 09:38","pubTimestamp":1784165919,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06990","BK1161","LU0196878994.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105297191","title":"港股开盘 | 三大指数高开，阿里巴巴涨超2%，智谱跌超7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1105297191","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105297191?lang=zh_cn&edition=full","pubTime":"2026-07-16 09:21","pubTimestamp":1784164868,"startTime":"0","endTime":"0","summary":"7月16日，港股三大指数高开，恒指涨0.58%，恒科指涨0.15%。科指成分股中，阿里巴巴-W涨2.47%，智谱跌7.26%，MINIMAX-W跌3.84%，华虹宏力跌3.72%，联想集团跌3.27%。生物医药板块多股高开，科伦博泰生物开涨4.19%，昭衍新药开涨1.89%。","market":"hk","thumbnail":"https://static.tigerbbs.com/09caddfc0c2d2ea28b3db992baa72dbf","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/09caddfc0c2d2ea28b3db992baa72dbf"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07200","LU0320764243.SGD","BK4505","00992","LU0890818403.SGD","LU0264606111.USD","LU0831093199.SGD","LU0329678170.USD","LU0823038988.USD","LU0561508036.HKD","HK0000107257.USD","LU0043850808.USD","LU0164872284.USD","LU1267930227.SGD","LU0163747925.USD","BK4524","LU0873338254.USD","LU1481107354.HKD","LU1051768304.USD","LU2488822045.USD","LU0052756011.USD","LU0630378429.USD","LU0611395673.USD","LU1880383440.USD","LU0651947912.USD","SG9999001226.SGD","BK1608","SG9999006597.SGD","IE00B5MMRT66.SGD","LU0229945570.USD","LU1568876251.USD","83115","BK4565","LU0545039389.USD","LU1282651121.HKD","LU1956131251.USD","LU0210526637.USD","LU0588545730.USD","LU2476274720.SGD","KBAB","LU1769817096.USD","LU0210527791.USD","IEMG","LU0106252389.USD","LU1813983027.USD","LU0164865239.USD","LU0165289439.USD","LU1044876610.USD","SG9999000459.SGD","SG9999002562.SGD","LU0128525689.USD","LU0320764599.SGD","LU2294711473.HKD","LU0594300419.USD","SGXZ86797644.SGD","LU1794554557.SGD","80992","BK1141","LU0661504455.SGD","LU1282648689.USD","LU2148611432.USD","82800","LU0061477393.USD","LU0516423174.USD","LU0127658192.USD","LU0541501648.USD","LU2097828631.EUR","LU0737861699.HKD","LU0543330566.HKD","LU0049853897.USD","LU1008478684.HKD","HBBD.SI","LU0106259558.USD","LU0886674414.USD","LU1688375341.USD","BK4220","LU1720050803.USD","LU1046421795.USD","BK4550","03115","LU0417516571.SGD","LU0370786039.SGD","LU0456842615.SGD","SG9999006514.SGD","LU2399975544.HKD","BK4607","LU1282649810.SGD","BKF","LU0047713382.USD","LU2125910849.SGD","LU0348784397.USD","LU0791590937.USD","LU2097828805.USD","LU0823041008.USD","LU0348783233.USD","LU0143863784.USD","LU1548497426.USD","LU1642822792.SGD","LU0865486749.SGD","IE00BFMHRM44.USD","LU0949170772.SGD","BK1193","LU1808992512.USD","CLIX","LU0577902371.SGD","HK0000320264.USD","BK4543","LU0197773160.USD","LU0315179316.USD","LU0084288322.USD","BK1584","DRAG","BK4558","LU0011963245.USD","LU0488056044.USD","07300","LU1810669033.SGD","LU0143863198.USD","LU0173614495.USD","BK1589","BABU","LU0449515922.USD","BABX","LU0052750758.USD","LU0502904849.HKD","LU0348827113.USD","SG9999002828.SGD","BK1575","BK4122","LU0593848301.USD","07500","LU0431992006.USD","LU1051769294.HKD","LU1366334578.USD","BK1142","LU0823413587.USD","LU0181495838.USD","BABW","LU0231483743.USD","LU0051755006.USD","LU1046422090.SGD","LU1235295612.USD","LU2097829019.USD","LU1105468828.SGD","IE00B0169N27.USD","SG9999002463.SGD","SGXZ90724238.SGD","LU0348788117.USD","LU0130103400.USD","IE00BZ08YR35.GBP","BK1591","LU1504937902.USD","LU1211504680.USD","LU1655091459.SGD","HK0000320223.HKD","LU0456846285.SGD","BK4535","LU2097828557.USD","LU0251143458.SGD","LU1115378108.SGD","LU0516422366.SGD","LU1568876335.HKD","LU1961090484.USD","LU0048580855.USD","BK4614","IE0003895053.USD","LU0605514214.HKD","LU0588545904.SGD","LU0117844026.USD","BK1586","LU1328615791.USD","LU0048597586.USD","LU0979878070.USD","LU0469268626.HKD","LU0589944569.HKD","BK1618","LU0054450605.USD","SG9999001903.USD","01347","BK1521","LU0738911758.USD","BK1607","LU0572939691.SGD","LU0823426308.USD","LU0516422952.EUR","LU2097828474.EUR","BK1588","LU0708995153.HKD","BK4538","LU0345776255.USD","LU0348814723.USD","SG9999001051.SGD","BK1163","LU0130518102.USD","LU3063872942.SGD","LU0348816934.USD","LU1282651048.USD","06990","LU0106959298.USD","LU1044874839.SGD","LDEM","LU0791591158.USD","LU1242518931.SGD","LU0039217434.USD","LU1880398554.USD","IE00BPRC5H50.USD","LU0675040207.SGD","LU0823039010.USD","LU0762541174.USD","LU0823413660.USD","LU0642271901.SGD","LU0235996351.USD","LU0856984785.SGD","LU1188198961.HKD","LU2476274308.USD","LU0149721374.USD","LU1366334651.USD","LU0456827905.SGD","09988","BK4504","SG9999004220.SGD","LU0821914370.USD","LU0329678337.USD","BK1615","LU0823397285.USD","LU0918141887.USD","KWEB","LU0762540952.USD","BK4588","LU0417516738.SGD","LU0359201885.HKD","00100","LU0608807946.USD","LU0477156797.USD","LU0762542818.HKD","BK1610","LU0310800965.SGD","LU0648948544.HKD","SG9999014674.SGD","LU0328353924.USD","LU1152091168.USD","LU0140636845.USD","BBYY","LU0553294199.USD","LU0577902298.EUR","LU0072913022.USD","LU1282649067.USD","LU0880133367.SGD","LU0577902454.USD","LU2152927971.USD","LU0348783662.USD","FDNI","LU0029874905.USD","LU0293314216.USD","LU0819123356.HKD","LU1981816686.USD","SG9999001093.SGD","LU0067412154.USD","LU0501845795.SGD","LU0117841782.USD","LU1823568750.SGD","LU0819121731.USD","LU0516423091.SGD","LU0128522157.USD","BK1526","LU0197773673.USD","LU0516422440.USD","IE00B3M56506.USD","VXUS","BK1161","BABO","LU0737861772.HKD","LU1439103000.SGD","BK4579","LU0868486357.SGD","LU2357305700.SGD","06127","LU0244354667.USD","LU0823397103.USD","LU0572944931.SGD","LU1720051017.SGD","LU1196710864.SGD","LU1720051108.HKD","LU0359201612.USD","IE00BMPRXN33.USD","HK0000306701.USD","LU0672654166.SGD","LU0871576103.HKD","ONLN","IE00BZ08YS42.EUR","LU0211977185.USD","LU0588546209.SGD","LU1282649141.HKD","LU2449936058.SGD","BABA","LU1251922891.USD","LU2257852520.SGD","LU0348805143.USD","LU0359202008.SGD","LU1515016050.SGD","LU2293587155.HKD","LU0259732245.USD","LU0348735423.USD","LU0828237940.HKD","LU1993786604.SGD","LU0828237510.HKD","LU2039709279.SGD","02800","BK4554","LU0441854154.USD","LU0327786744.USD","LU1719994722.HKD","CXSE","LU1770034418.SGD","LU0577902538.SGD","LU0608807433.USD","LU1044875133.USD","LU0700851271.USD","BK1614","LU1880383366.USD","LU1328277881.USD","IE00BZ08YT58.USD","LU0314109678.HKD","LU0345775950.USD","BK4581","LU1831875114.USD","SG9999000327.SGD","LU0862451753.SGD","09115","LU1048596156.SGD","BK4533","BK4587","LU0540923850.HKD","LU0261947096.USD","TCHI","LU1003077747.HKD","LU0630378692.HKD","LU1235294995.USD","LU0531970944.HKD","LU0228367735.SGD","LNVGY","LU0164880469.USD","LU1769817179.HKD","LU1880398471.USD","LU0831103253.SGD","LU0640798160.USD","LU0261950983.USD","LU0132412106.USD","SGXZ62798434.SGD","LU0784639295.USD","LU1048588211.SGD","LU1224709979.USD","LU0169518387.USD","BK4534","IE0034224299.USD","BK4502","LU0797268264.HKD","LU0708995583.HKD","BK4575","BK4531","LU0228659784.USD","LU0449509016.USD","LU1152091754.HKD","BK4503","03419","LU0577902611.USD","LU0348825331.USD","LU0499858438.USD","LU0049112450.USD","LU0048388663.USD","LU2045819591.USD","LU0862451837.USD","LU0096374516.USD","LU0417516902.SGD","LU0384037296.USD","LU2226246903.HKD","BK4527","LU1023057109.AUD","IE00B543WZ88.USD","HK0000151867.HKD","LU0214875030.USD","LU0326950275.SGD","LU1242518857.USD","LU0918141705.HKD","LU0823040885.USD","02513","BK4548","BK1249","LU0823426480.USD","BK1501","LU0607220059.USD","LU2778985437.USD","LU0251144936.SGD","LU1807302812.USD","LU1224444064.USD","LU0588545490.SGD","BK1117","LU0320764755.SGD","LU1048484197.HKD","LU0463099449.HKD","LU0196878994.USD","LU0651946864.USD","LU0315178854.USD","LU1316542783.SGD","LU0531971595.HKD","LU1770036033.HKD","LU2087589342.USD","IE0032431581.USD","LU0054237671.USD","LU0128522744.USD","IE00B0JY6N72.USD","IE00BF5LJ272.USD","LU2125910500.SGD","LU0029875118.USD","SG9999001689.USD","LU0287142896.SGD","LU0898667661.SGD","03037","HSI","LU0543330483.HKD","LU0634319403.HKD","LU0072462343.USD","LU1303224171.USD","LU1201861165.SGD","LU0648000940.SGD","BK1576","89988","LU0254981946.USD","IE00BMPRXR70.SGD","HK0000286598.CNH","EDZ","LU1868838027.USD","LU1960683339.HKD","LU1323998911.USD","LU1868837565.USD","LU0594300179.USD","HK0000306685.HKD","KCAI","BK4585","LU0541502299.USD","LU2097828714.EUR","LU2242644610.SGD","BK1517","LU0149534421.HKD","LU0307460666.USD","BK4526","ALBmain","BK1502","LU0499858602.USD","IE0008368304.USD","LU0455707207.USD","LU0396098781.USD","LU0572940350.SGD","LU0650527681.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651482466","title":"默沙东股价上涨3%，因其合作伙伴科伦博泰公布可瑞达肺癌关键研究取得积极结果。","url":"https://stock-news.laohu8.com/highlight/detail?id=2651482466","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651482466?lang=zh_cn&edition=full","pubTime":"2026-07-15 21:34","pubTimestamp":1784122489,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PPH","BK1161","SG9999013999.USD","IE000M9KFDE8.USD","IHE","MRK","LU1983299246.USD","IE00BJJMRZ35.SGD","BK4007","LU1291159041.SGD","LU0234572021.USD","LU2361044865.SGD","LU1941712348.USD","LU2023250843.SGD","LU1989772923.USD","LU0985320562.USD","IE00BN8TJ469.HKD","LU2360032135.SGD","SG9999001440.SGD","LU0070302665.USD","LU2491049909.HKD","IE00BSNM7G36.USD","LU1571399168.USD","SG9999001176.USD","LU1116320901.HKD","JDOC","LU1066053197.SGD","IE00B4R5TH58.HKD","LU0965508806.USD","SG9999014575.USD","LU0320765646.SGD","LU0196878994.USD","BK4534","SG9999014567.USD","IE00BJT1NW94.SGD","LU2461242641.AUD","LU1923622614.USD","VHT","LU0058720904.USD","LU0211331839.USD","LU1066051811.HKD","SG9999002224.SGD","LU1934455277.USD","LU2089984988.USD","SG9999002232.USD","LU2023250504.SGD","IE00BLSP4452.SGD","BK4588","IE00B1BXHZ80.USD","LU0965509010.AUD","BMED","LU1037948541.HKD","LU1061106388.HKD","LU0289739699.SGD","IXJ","LU2324357040.USD","LU0130102774.USD","LU2361045086.USD","LU0320765489.SGD","BK4559","LU0868494617.USD","LU0868494708.USD","LU2361044949.HKD","LU0124676726.USD","LU0122379950.USD","LU1934455194.USD","LU0689626769.HKD","LU0432979614.USD","LU2125909247.SGD","LU0965509101.SGD","FHLC","IE00B2B36J28.USD","IE00BLSP4239.USD","LU1069347547.HKD","HRTS","BK4533","LU2125154935.USD","LU0942090050.USD","LU1023059063.AUD","LU1037948897.HKD","IE0002141913.USD","LU0238689110.USD","BK4585","RXL","PAWZ","LU1430594728.SGD","LU1917777945.USD","IYH","LU1699723380.USD","LU1116320737.USD","SG9999014559.SGD","LU0477156953.USD","IE0009355771.USD","LU1974910355.USD","LU1162221912.USD","LU2491050071.SGD","LU0208291251.USD","LU1989772840.SGD","BK4550","LU0130517989.USD","LU2433249047.HKD","LU2106854487.HKD","LU1929549753.HKD","06990","LU2125909593.SGD","LU1066051225.USD","LU0203345920.USD","LU2112291526.USD","LU1989771016.USD","LU0265550946.USD","SG9999014542.SGD","SG9999001176.SGD","LU0203347892.USD","SG9999015358.SGD","LU1934455863.HKD","GDOC","LU0006306889.USD","LU0265550359.USD","LU0648001328.SGD","LU0266013472.USD","LU1941712264.USD","SG9999015341.SGD","LU0965509283.SGD","LU0098860793.USD","BK4516","LU0859254822.USD","IE00BFTCPJ56.SGD","LU2491050154.USD","LU1093756325.SGD","LU2125154778.USD","SGXZ57979304.SGD","LU0106261372.USD","LU1201861249.SGD","IE00BBT3K403.USD","LU0980610538.SGD","LU2468319806.SGD","LU1066051498.USD","XLV","FTXH","LU0861579265.USD","LU1093756168.USD","LU2357627491.SGD","LU1057294990.SGD","LU1035773651.USD","LU1585245621.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651745225","title":"科伦博泰生物27亿港元配售补充研发资金 上市三年累计融资近70亿港元 融资规模位于18A企业前列","url":"https://stock-news.laohu8.com/highlight/detail?id=2651745225","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651745225?lang=zh_cn&edition=full","pubTime":"2026-07-15 18:52","pubTimestamp":1784112720,"startTime":"0","endTime":"0","summary":"7月10日，科伦博泰生物-B发布公告，顺利完成新一轮H股配售工作，本次配售募集资金净额约27.23亿港元。这家2023年登陆港交所18A平台的创新生物企业，上市三年间已开展多轮股权募资，持续加码管线研发。　　梳理上市后融资脉络：2023年IPO、2024年5月、2025年6月、2026年7月四轮股权融资，上市三年累计股权募资规模接近70亿港元，在港股18A药企中融资频次与规模均处于较高区间。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-07-15/doc-inihwvxc7918848.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","LU0196878994.USD","06990","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108471273","title":"科伦博泰生物与和铂医药宣布SKB575/HBM7575治疗哮喘新药临床试验申请获中国药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1108471273","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108471273?lang=zh_cn&edition=full","pubTime":"2026-07-15 18:03","pubTimestamp":1784109826,"startTime":"0","endTime":"0","summary":"科伦博泰生物与和铂医药共同宣布，其合作开发的创新药物SKB575/HBM7575用于治疗哮喘的新药临床试验（IND）申请，已获得中国国家药品监督管理局（NMPA）的正式批准。\n这一重要监管里程碑标志着该候选药物将在中国正式进入临床开发阶段，为哮喘患者带来新的潜在治疗选择。SKB575/HBM7575是一款由双方联合研发的靶向疗法，其获批开展临床试验是基于充分的临床前研究数据，展示了良好的安全性和潜在疗效。\n两家公司表示，将尽快推进该药物的后续临床研究工作，以评估其在哮喘患者中的安全性、耐受性及有效性。此次获批也进一步巩固了科伦博泰生物与和铂医药在创新生物药研发领域的战略合作与管线实力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06990","LU0196878994.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651810439","title":"港股早盘高开高走 恒指半日涨1.46% 创新药、猪肉概念强势","url":"https://stock-news.laohu8.com/highlight/detail?id=2651810439","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651810439?lang=zh_cn&edition=full","pubTime":"2026-07-15 12:11","pubTimestamp":1784088667,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股早盘高开高走，三大股指均升逾1%。截至午间收盘，恒生指数上涨1.46%；国企指数涨1.16%；恒生科技指数涨1.39%。猪价底部大概率已现，预计周期临近上行。预计2026年半年度归属于上市公司股东的扣除非经常性损益的净利润约为人民币20.00亿元到人民币26.00亿元，与上年同期相比，将增加人民币18.62亿元到人民币24.62亿元，同比增长1349%到1784%。MiniMax盘中反复拉升，午间收涨14.96%。港股将受益于中国内地强劲而有韧性的经济表现，建议超配H股。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/YWY0NWM4YTUxZGFlZmZjNmE5MDYxNjI4NjU1Mjc3NzM1Mzg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YWY0NWM4YTUxZGFlZmZjNmE5MDYxNjI4NjU1Mjc3NzM1Mzg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985921","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0456846285.SGD","LU0169518387.USD","LU0588545730.USD","LU1046422090.SGD","BK1528","LU0588545490.SGD","LU0531971595.HKD","LU1675838814.USD","82800","LU0880133367.SGD","LU1719994722.HKD","LU0315179316.USD","02269","LU2045819591.USD","LU1961090484.USD","01093","BK1526","LU1152091754.HKD","LU0211977185.USD","LU1969619763.USD","002714","LU0819121731.USD","LU2328871848.SGD","BK1161","LU1831875114.USD","LU0865486749.SGD","LU0979878070.USD","LU0588545904.SGD","LU0043850808.USD","LU1951186391.HKD","SG9999004220.SGD","BK1515","LU0196878994.USD","LU0417516738.SGD","LU1023057109.AUD","LU1048596156.SGD","07300","BK1584","LU0072462343.USD","688981","01801","600028","601857","LU1051769294.HKD","LU1226288170.HKD","SG9999012744.USD","LU0634319403.HKD","BK1523","IE00BZ08YR35.GBP","02833","HK0000165453.HKD","LU0181495838.USD","LU1813983027.USD","07500","LU0348766576.USD","LU0455707207.USD","LU0359201612.USD","LU0463099449.HKD","LU0516422366.SGD","BK1172","LU1808992512.USD","LU2488822045.USD","BK1550","SG9999012728.SGD","LU1497734951.SGD","LU1807302812.USD","LU0823426480.USD","BK1184","03037","LU0348767384.USD","83115","HSTECH","BK1610","BK1163","LU1497733631.SGD","LU1993786604.SGD","BK1191","LU2039709279.SGD","HHImain","LU1634259557.SGD","LU0871576103.HKD","BK1506","SG9999002463.SGD","LU0501845795.SGD","LU0359201885.HKD","00857","02628","BK1574","IE0032431581.USD","LU0348784397.USD","BK1237","LU2476274308.USD","LU1211504680.USD","LU0651947912.USD","07200","601869","LU0164865239.USD","LU0502904849.HKD","LU0173614495.USD","SG9999001226.SGD","LU0708995583.HKD","LU0359202008.SGD","BK1141","LU0862451837.USD","02714","LU1634259391.SGD","00100","LU0516422440.USD","LU0651946864.USD","BK1603","603259","BK1576","LU1515016050.SGD","LU0561508036.HKD","LU2097828805.USD","LU0348735423.USD","LU0348825331.USD","SG9999014674.SGD","SCHYY","LU0675040207.SGD","03419","01177","IE00B5MMRT66.SGD","LU0405327494.USD","LU0326950275.SGD","LU1522347837.USD","LU0327786744.USD","LU1051768304.USD","LU1770034418.SGD","BK1589","IE0008368742.USD","00981","IE00B19Z5X02.USD","LU0067412154.USD","LU0469268626.HKD","LU2778985437.USD","LU1226287875.USD","SG9999012710.SGD","LU1226288253.USD","LU0441854154.USD","01477","09926","LU0244354667.USD","LU0572944931.SGD","BK1607","LU1720050803.USD","LU1008478684.HKD","LU1251922891.USD","LU0320764599.SGD","LU2125910500.SGD","MCHmain","LU0823426308.USD","LU1328277881.USD","IE0008369823.USD","SG9999003461.SGD","LU1960683339.HKD","LU0856984785.SGD","LU0862451753.SGD","LU1115378108.SGD","IE00BZ08YS42.EUR","LU2293587155.HKD","LU0315178854.USD","06869","LU1226287792.SGD","SG9999006597.SGD","LU0588546209.SGD","LU1226287529.USD","BK1149","SG9999001093.SGD","LU0287142896.SGD","IE00BPRC5H50.USD","601628","SGXZ62798434.SGD","WXXWY","LU1282651048.USD","SGXZ86797644.SGD","LU0348827113.USD","LU2097828714.EUR","BK1583","LU2242644610.SGD","02800","IE00BWDBJ730.SGD","LU1794554557.SGD","09115","LU0516423091.SGD","IE00B543WZ88.USD","LU1152091168.USD","LU1048588211.SGD","LU2399975544.HKD","LU0307460666.USD","LU0972618739.USD","LU0140636845.USD","LU0405327148.USD","LU0417516571.SGD","IE00B0JY6N72.USD","LU0516423174.USD","LU1188198961.HKD","LU1880383366.USD","LU0348783233.USD","LU0251144936.SGD","02359","LU0540923850.HKD","LU2097828631.EUR","LU0048597586.USD","06990","LU1785774172.SGD","LU1242518931.SGD","LU0293314216.USD","LU1282651121.HKD","BK1226","LU1303224171.USD","LU2257852520.SGD","LU0072913022.USD","LU0611395673.USD","LU2097828474.EUR","BK1549","SG9999002562.SGD","BK1117","BK1562","02419","00386","KURE","LU0314109678.HKD","LU0456827905.SGD","LU0516422952.EUR","LU1688375341.USD","LU1242518857.USD","LU0821914370.USD","HSI","02268","LU3063872942.SGD","LU0828237940.HKD","LU0348783662.USD","LU0890818403.SGD","LU0052750758.USD","BK1614","LU0228367735.SGD","01928","03115","513600","LU0051755006.USD","LU0163747925.USD","LU2476274720.SGD","LU0039217434.USD","LU0640798160.USD","LU0348805143.USD","01610","IE00BZ08YT58.USD","BK1521","SG9999012736.USD","LU1497733557.USD","LU2097828557.USD","IE00BQJZWZ67.USD","LU0417516902.SGD","SBHMY","HK0000286598.CNH","LU1224444064.USD","IE00B031HY20.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651291435","title":"创新药概念全线扬升 科伦博泰生物(06990)涨逾11% 机构指创新药企迎业绩兑现窗口","url":"https://stock-news.laohu8.com/highlight/detail?id=2651291435","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651291435?lang=zh_cn&edition=full","pubTime":"2026-07-15 11:07","pubTimestamp":1784084836,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股创新药概念盘中全线扬升，截至发稿，欧康维视生物-B 涨13.35%，科伦博泰生物涨11.20%，康方生物涨8.82%，信达生物涨8.72%，三生制药涨8.11%，康诺亚-B涨7.62%，药明合联涨7.52%，荣昌生物涨7.09%，乐普生物涨6.87%，亚盛医药涨6.26%。该机构持续看好国内创新药出海β向上可持续性，提示投资者关注2027年起众多前期已达成BD的分子将在海外开启商业化新周期所带来的投资机会。","market":"fut","thumbnail":"https://static.szfiu.com/news/20200908/MDgxZGVmMDU5NGQxM2FkZGQzODVkYTY4OWM4NjkxNzk5NzY4NzQ2MDU0.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/MDgxZGVmMDU5NGQxM2FkZGQzODVkYTY4OWM4NjkxNzk5NzY4NzQ2MDU0.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985914","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348825331.USD","LU2476274308.USD","01530","LU0561508036.HKD","LU0417516902.SGD","06990","BK1191","02157","BK1161","BK1593","MEDX","SG9999014674.SGD","01477","LU0455707207.USD","LU0540923850.HKD","LU2097828631.EUR","BK1574","LU0348827113.USD","06855","01801","BK1587","LU0348767384.USD","LU0348784397.USD","09926","KURE","LU2328871848.SGD","LU0417516738.SGD","LU2097828805.USD","06978","LU1720050803.USD","IBBQ","IE00BPRC5H50.USD","LU0502904849.HKD","BK1583","LU2097828714.EUR","02162","159992","02268","09995","LU2399975544.HKD","LU0634319403.HKD","IE00B543WZ88.USD","LU0417516571.SGD","BK1141","LU2097828474.EUR","LU2778985437.USD","LU1961090484.USD","LU2097828557.USD","LU2488822045.USD","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132262891","title":"异动解读｜科伦博泰生物盘中上涨10.8%，核心产品联治PD-L1阴性NSCLC三期研究达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1132262891","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132262891?lang=zh_cn&edition=full","pubTime":"2026-07-15 10:38","pubTimestamp":1784083130,"startTime":"0","endTime":"0","summary":"7月15日，科伦博泰生物盘中上涨10.8%，报552.0港元，成交额4.64亿港元。消息面上，公司宣布核心产品TROP2 ADC芦康沙妥珠单抗联合帕博利珠单抗一线治疗PD-L1阴性局部晚期或转移性非鳞状非小细胞肺癌的三期临床研究已达到主要终点，安全性与既往研究一致，未观察到新的安全性信号。此前公司已在ASCO大会披露sac-TMT联合K药一线治疗PD-L1阳性NSCLC的三期阳性结果，本次PD-L1阴性适应症的突破进一步扩大其覆盖人群范围。目前公司已在中国开展9项注册性临床研究。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651661433","title":"港股异动 | 科伦博泰生物(06990.HK)涨超11% 核心产品联治PD-L1阴性NSCLC 3期研究达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2651661433","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651661433?lang=zh_cn&edition=full","pubTime":"2026-07-15 09:59","pubTimestamp":1784080756,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0196878994.USD","BK1161","06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651348206","title":"科伦博泰生物(06990)：核心产品TROP2ADC芦康沙妥珠单抗(sac-TMT)联合帕博利珠单抗一线治疗PD-L1阴性局部晚期或转移性非鳞状非小细胞肺癌3期临床研究达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2651348206","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651348206?lang=zh_cn&edition=full","pubTime":"2026-07-15 07:32","pubTimestamp":1784071939,"startTime":"0","endTime":"0","summary":"安全性方面，芦康沙妥珠单抗联合帕博利珠单抗的安全性特征与既往研究报告一致，未观察到新的安全性信号。目前，本公司已在中国开展9项注册性临床研究。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1467588.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0196878994.USD","LU1169589451.USD","PD","LU1169590202.USD","06990","BK1161","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153250740","title":"科伦博泰生物Trop2 ADC联合帕博利珠单抗三期研究达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1153250740","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153250740?lang=zh_cn&edition=full","pubTime":"2026-07-15 07:24","pubTimestamp":1784071456,"startTime":"0","endTime":"0","summary":"科伦博泰生物宣布，其靶向Trop2的抗体药物偶联物Sacituzumab Tirumotecan联合帕博利珠单抗的三期临床研究已达到主要终点。该研究旨在评估联合疗法在特定适应症中的疗效与安全性。此次成功是科伦博泰生物在ADC领域研发实力的又一体现。公司表示，将进一步分析详细数据，并与监管机构沟通后续事宜。这一里程碑事件有望推动该创新疗法早日惠及患者，并为公司带来新的增长动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990","LU0196878994.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651201271","title":"国联民生证券：晚期一线肺癌治疗领域仍有广阔提升空间 关注科伦博泰(06990)sac-TMT全球研发进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2651201271","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651201271?lang=zh_cn&edition=full","pubTime":"2026-07-14 15:26","pubTimestamp":1784013964,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国联民生证券发布研报称，当前晚期一线肺癌治疗领域仍有广阔提升空间。其中在PD-1单抗+ADC路线中，科伦博泰及其合作方默沙东就sac-TMT的布局兼具适应症覆盖范围与较高的成功概率，有望在这一路线中胜出。同时默沙东留有PD-1双抗与sac-TMT联用的战略后手，建议重点关注科伦博泰sac-TMT的全球研发进展。整体来看，PD-1单抗已在一线肺癌市场取得了胜利。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1467119.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2778985437.USD","BK1557","IE00BZ08YS42.EUR","LU0877626530.USD","IE00BYV24P56.USD","LU2476274308.USD","BK1214","IE00BZ08YR35.GBP","IE00B543WZ88.USD","161027","LU2048586759.USD","BK0276","BK1564","IE0008368742.USD","IE00BZ08YT58.USD","LU0890818403.SGD","BK1161","LU0205439572.USD","IE0034224299.USD","LU1115378108.SGD","IE00B031HY20.USD","IE00B5MMRT66.SGD","06990","LU0431992006.USD","IE00B29SXG58.USD","01456","LU2279701549.SGD","IE00BMCWC346.EUR","LU0196878994.USD","LU0862451753.SGD","LU1655091616.SGD","BK1147","BK1607","06690","601456","LU0593848301.USD","IE0008369823.USD","LU0640798160.USD","IE00BPRC5H50.USD","LU1119993845.HKD","LU0868486357.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://kelun-biotech.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0.2121},{"period":"3month","weight":0.007},{"period":"6month","weight":0.1737},{"period":"1year","weight":0.297},{"period":"ytd","weight":0.2851}],"compareEarnings":[{"period":"1week","weight":0.0384},{"period":"1month","weight":0.0509},{"period":"3month","weight":-0.0508},{"period":"6month","weight":-0.0542},{"period":"1year","weight":0.0128},{"period":"ytd","weight":-0.019}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"四川科伦博泰生物医药股份有限公司是一家主要从事新药业务的研发、生产和销售的中国公司。该公司主要从事肿瘤学、免疫学及其他治疗领域的创新药物的研发、制造及商业化。该公司的产品有抗体药物偶联物（ADC）SKB264和A166等。该公司产品主要用于乳腺癌、非小细胞肺癌、胃肠道癌等疾病的治疗。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.05939},{"month":2,"riseRate":0.666667,"avgChangeRate":0.239909},{"month":3,"riseRate":1,"avgChangeRate":0.292496},{"month":4,"riseRate":1,"avgChangeRate":0.083557},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.011152},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.022649},{"month":7,"riseRate":0.666667,"avgChangeRate":0.126594},{"month":8,"riseRate":1,"avgChangeRate":0.047459},{"month":9,"riseRate":1,"avgChangeRate":0.084769},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.03489},{"month":11,"riseRate":1,"avgChangeRate":0.072292},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.053467}],"exchange":"SEHK","name":"科伦博泰生物","nameEN":"SKB BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"科伦博泰生物(06990)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供科伦博泰生物(06990)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"科伦博泰生物,06990,科伦博泰生物股票,科伦博泰生物股票老虎,科伦博泰生物股票老虎国际,科伦博泰生物行情,科伦博泰生物股票行情,科伦博泰生物股价,科伦博泰生物股市,科伦博泰生物股票价格,科伦博泰生物股票交易,科伦博泰生物股票购买,科伦博泰生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"科伦博泰生物(06990)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供科伦博泰生物(06990)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}